News articles about Accuray (NASDAQ:ARAY) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Accuray earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.1299807426993 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Analysts’ Review under Consideration: Accuray Incorporated (ARAY) – AppsforPCdaily (appsforpcdaily.com)
- Accuray Incorporated (ARAY) Needs Strong Boost to Get Active Moment in Street – Stock News Stop (stockmarketstop.com)
- Analysts’ Report Recap: Accuray Incorporated (ARAY) – ExpertGazette (expertgazette.com)
- Accuray Incorporated (NASDAQ:ARAY) – Is the Stock Safe to Invest? – Nasdaq Journal (press release) (nasdaqjournal.com)
- Beverly A. Huss Joins Accuray Board of Directors – PR Newswire – PR Newswire (press release) (prnewswire.com)
Several research firms have issued reports on ARAY. Cowen reaffirmed a “buy” rating and set a $9.00 price target on shares of Accuray in a research report on Friday, October 27th. Zacks Investment Research lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. JPMorgan Chase & Co. lowered shares of Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 price target on the stock. in a research report on Wednesday, December 13th. BidaskClub lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, Lake Street Capital began coverage on shares of Accuray in a research report on Thursday, November 30th. They set a “buy” rating and a $10.00 price target on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.82.
Accuray (NASDAQ:ARAY) opened at $5.05 on Friday. Accuray has a fifty-two week low of $3.60 and a fifty-two week high of $6.00. The company has a market cap of $411.20, a price-to-earnings ratio of -14.85 and a beta of 1.29. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.48 and a quick ratio of 0.92.
Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Accuray had a negative net margin of 7.49% and a negative return on equity of 55.18%. The firm had revenue of $91.00 million for the quarter, compared to the consensus estimate of $88.26 million. During the same period in the previous year, the company earned ($0.12) earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. equities research analysts predict that Accuray will post -0.23 EPS for the current year.
In other Accuray news, CFO Kevin Waters sold 7,154 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $5.06, for a total value of $36,199.24. Following the transaction, the chief financial officer now directly owns 335,087 shares in the company, valued at $1,695,540.22. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joshua Levine sold 17,093 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $4.86, for a total transaction of $83,071.98. Following the completion of the transaction, the chief executive officer now owns 1,435,428 shares in the company, valued at $6,976,180.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,413 shares of company stock worth $129,798. Corporate insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thestockobserver.com/2018/01/13/accuray-aray-receiving-somewhat-positive-media-coverage-analysis-finds.html.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.